+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group



Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group



Pediatric Infectious Disease Journal 17(12): 1144-1148



To determine the prevalence and outcome of intravenous gamma-globulin (IVIG) retreatment in patients with Kawasaki disease (KD). Multicenter, retrospective survey of all children with KD evaluated at nine clinical centers across North America during a 15-month period. Data were available for 378 patients. At 48 h after completion of the initial IVIG infusion, 50 patients (13.2%) remained febrile, 29 (58.0%) of whom were retreated with IVIG, including 4 (13.8%) with coronary artery abnormalities before their first IVIG infusion. Among 25 retreated patients with a normal baseline echocardiogram, 5 (20.0%) developed coronary abnormalities and were termed "treatment failures." Among the 323 patients with a normal baseline echocardiogram, only 9 (2.8%) were treatment failures; treatment failure occurred in 4 of 282 (1.4%) patients who became afebrile post-IVIG and in 5 of 41 (12.2%) patients with persistent or recrudescent fever after their first course of IVIG therapy (P=0.002). The overall prevalence of new coronary abnormalities in KD patients treated with IVIG and aspirin remains low. Persistent or recrudescent fever after the first course of IVIG was associated with an increased risk of treatment failure (P=0.002). IVIG retreatment in patients who remain febrile after the first course of IVIG is now common (58.0%), although the efficacy of this practice requires assessment with a randomized trial.

(PDF emailed within 1 workday: $29.90)

Accession: 046458283

Download citation: RISBibTeXText

PMID: 9877364


Related references

Intravenous gamma globulin treatment and retreatment in Kawasaki disease. Clinical Infectious Diseases 25(2): 423, 1997

Early intravenous gamma globulin retreatment for refractory Kawasaki disease. Clinical Pediatrics 42(3): 269-272, 2003

The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine 315(6): 341-347, 1986

Treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine 316(14): 881, 1987

Intravenous gamma globulin treatment for Kawasaki disease. Nichidai Igaku Zasshi 51(8): 783-786, 1992

Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatrica Japonica 33(6): 805-810, 1991

Intravenous gamma globulin in the treatment of Kawasaki Syndrome Are all brands equal?. Pediatric Research 37(4 PART 2): 171A, 1994

A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine 324(23): 1633-1639, 1991

Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. Journal of Pediatrics 144(4): 496-499, 2004

Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. Journal of Pediatrics 146(1): 149-50; Author Reply 150-1, 2005

Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. Journal of Pediatrics 137(2): 177-180, 2000

Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease. Kaohsiung Journal of Medical Sciences 21(9): 401-404, 2005

The efficacy of a single intravenous infusion of gamma globulin in the treatment of acute Kawasaki disease. Japanese Circulation Journal 58(7): 541, 1994

Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease. Zhonghua Yi Xue Za Zhi 89(26): 1841-1843, 2010

Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Modern Rheumatology 14(5): 361-366, 2006